fulvestrant

Type: Keyphrase
Name: fulvestrant
First reported 9 hours ago - Updated 9 hours ago - 1 reports

The Soy, Breast Cancer Connection

Today we are discussing the link between soy consumption and breast cancer. We are speaking with Jacqueline F. Bromberg, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, who treats patients with breast cancer and does work on the role ... [Published Cancernetwork.com - 9 hours ago]
First reported 17 hours ago - Updated 17 hours ago - 1 reports

ESO-ESMO Consensus Guidelines for Advanced Breast Cancer

Cardoso F. Metastatic breast cancer patients: the forgotten heroes! The Breast 2009;18:271–272.Largillier R, Ferrero J-M, Doyen J, et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 2008;19:2012–2019.Andre F, Slimane K, Bachelot ... [Published General Medicine eJournal - 17 hours ago]
First reported Oct 22 2014 - Updated Oct 22 2014 - 3 reports

HER2 Positive Breast Cancer Drug Market to 2023: US, China and Japan Analysis With Forecasts

RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports for United States The says currently, treatment rates for HER2-positive breast cancer in China HER2-positive breast cancer ... [Published Industrial Info Financials - Oct 22 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Different Transcriptional Responses to Fulvestrant  and Estrogen Deprivation in ER-Positive Breast Cancer

By Matthew StengerOctober 15, 2014, Volume 5, Issue 16In a study reported in Clinical Cancer Research , Patani and colleagues investigated whether distinct transcriptional responses were associated with the reported increased effectiveness of the estrogen ... [Published The ASCO Post - Oct 15 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Pfizer's Breast Cancer Candidate Gets Priority Review - Analyst Blog

With the palbociclib NDA being submitted in August this year, a response from the FDA regarding its approval status should be out by Apr 13, 2015. The NDA is based on final results from the phase II PALOMA-1 study.Pfizer is currently conducting two phase ... [Published Nasdaq - Oct 15 2014]
First reported Oct 13 2014 - Updated Oct 14 2014 - 1 reports

Breakthrough Breast Cancer Treatment Granted FDA Priority Review

The FDA today granted priority review status to a breakthrough breast cancer drug developed by Pfizer Inc.Combined with letrozole, palbociclib is a treatment for postmenopausal women with estrogen receptor positive (ER+) and human epidermal growth factor ... [Published Pharmacy Times - Oct 13 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Roche could lose its dominant market share in breast cancer, says IMS report

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs, such as those from Swiss oncology giant Roche (ROG: SIX), according to a new webinar from IMS Health.Breast Cancer Targeting - Opportunities and Challenges ... [Published Pharma Letter - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Breast cancer drug sales will almost double by 2023, says IMS

Sales of breast cancer treatments are set to increase by an average of 5.8% a year in nine major markets, increasing from a value of $9.8 billion in 2013 to $18.2 billion by 2023, according to new forecasts from IMS Health. The highest-growing segment ... [Published Pharma Times - Oct 02 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

Breast cancer patients miss out on management plans

Chronic disease management plans should be routinely offered to secondary breast cancer patients, according to a national report that found four in five patients are missing out on the medical and financial benefits of subsidised care.Only 21% of women ... [Published Australian Doctor - Oct 01 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

CLOVIS ONCOLOGY : Reports on Lucitanib Phase 2 Study

Clovis Oncology reported that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site."Early lucitanib data are encouraging, and suggest that determination of ... [Published 4 Traders - Sep 24 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Chronic

Recently I was dining with friends, enjoying a pleasant Palo Alto evening on their porch. We noticed a family of quail walking on the ledge of the wooden fence that enclosed the yard, a mother and her brood of children. They hopped down into the yard. ... [Published Oncology Times - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 1 reports

Researchers examine role of hormone in response to ovarian cancer treatment

PUBLIC RELEASE DATE: 17-Sep-2014The work comes out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, of Women & Infants' Program in Women's Oncology. Entitled "HE4 expression is associated with hormonal elements and mediated by ... [Published EurekAlert! - Sep 17 2014]

Quotes

"Women with breast cancer should be encouraged to discuss management plan options with their GP" the report concluded, adding that breast cancer specialists should communicate with GPs about putting management plans in place
Infringement of U S Patent Nos. 8,017,615 ( "Low Hygroscopic Aripiprazole Drug Substance and Process for the Preparation Thereof" issued September 13, 2011), 8,580,796 (same title, issued November 12, 2013), and 8,642,760 (same title, issued February 4, 2014) following a Paragraph...
...FGF-aberrant breast cancer, which complements the Servier programs already underway," said Patrick Mahaffy , President and CEO of Clovis Oncology . "The PhasePhase 1/2a data presented to date are compelling and we look forward to confirming the optimal dose and schedule of lucitanib in this study."
"I am pleased to join the Array team at such an exciting time in the company's evolution," said Dr. Sandor. "In addition to the impressive portfolio of clinical-stage assets in development by Array's partners, I look forward to focusing on the development of binimetinib and filanesib, which each target patient populations with significant unmet medical need."

More Content

All (25) | News (24) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
The Soy, Breast Cancer Connection [Published Cancernetwork.com - 9 hours ago]
ESO-ESMO Consensus Guidelines for Advanced Brea... [Published General Medicine eJournal - 17 hours ago]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Industrial Info Financials - Oct 22 2014]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Indianapolis Business Journal - Oct 22 2014]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Scottrade - Oct 22 2014]
Different Transcriptional Responses to Fulvestr... [Published The ASCO Post - Oct 15 2014]
Pfizer's Breast Cancer Candidate Gets Priority ... [Published Nasdaq - Oct 15 2014]
Pfizer's Breast Cancer Candidate Gets Priority ... [Published Zacks.com - Oct 14 2014]
Breakthrough Breast Cancer Treatment Granted FD... [Published Pharmacy Times - Oct 13 2014]
Pfizer Announces FDA Acceptance Of Palbociclib ... [Published I Stock Analyst - Oct 13 2014]
Roche could lose its dominant market share in b... [Published Pharma Letter - Oct 03 2014]
Breast cancer drug sales will almost double by ... [Published Pharma Times - Oct 02 2014]
Breast cancer patients miss out on management p... [Published Australian Doctor - Oct 01 2014]
Court Report - September 2014 #6 [Published JD Supra - Sep 29 2014]
CLOVIS ONCOLOGY : Reports on Lucitanib Phase 2 ... [Published 4 Traders - Sep 24 2014]
Chronic [Published Oncology Times - Sep 19 2014]
Array BioPharma, Inc. (ARRY) Appoints Victor Sa... [Published FierceBiotech - Sep 19 2014]
Researchers examine role of hormone in response... [Published EurekAlert! - Sep 17 2014]
Court Report - September 2014 #4 [Published JD Supra - Sep 15 2014]
Mount Kisco Medical Group and Northern Westches... [Published PRWeb - Jun 24 2014]
Pfizer to submit palbociclib NDA with US FDA ba... [Published PharmaBiz - May 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer’s novel CDK 4/6 inhibitor palbociclib pl... [Published PharmaBiz - Apr 07 2014]
Fulvestrant 500 mg vs 250 mg in CONFIRM Trial [Published BioPortfolio - Feb 13 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.